These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 23225880)

  • 1. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy.
    Bologna L; Gotti E; Da Roit F; Intermesoli T; Rambaldi A; Introna M; Golay J
    J Immunol; 2013 Jan; 190(1):231-9. PubMed ID: 23225880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
    Bologna L; Gotti E; Manganini M; Rambaldi A; Intermesoli T; Introna M; Golay J
    J Immunol; 2011 Mar; 186(6):3762-9. PubMed ID: 21296976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
    Pawluczkowycz AW; Beurskens FJ; Beum PV; Lindorfer MA; van de Winkel JG; Parren PW; Taylor RP
    J Immunol; 2009 Jul; 183(1):749-58. PubMed ID: 19535640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.
    Beurskens FJ; Lindorfer MA; Farooqui M; Beum PV; Engelberts P; Mackus WJ; Parren PW; Wiestner A; Taylor RP
    J Immunol; 2012 Apr; 188(7):3532-41. PubMed ID: 22368276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab.
    Sebejova L; Borsky M; Jaskova Z; Potesil D; Navrkalova V; Malcikova J; Sramek M; Doubek M; Loja T; Pospisilova S; Mayer J; Trbusek M
    Exp Hematol; 2014 Oct; 42(10):867-74.e1. PubMed ID: 24970561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.
    Ge X; Wu L; Hu W; Fernandes S; Wang C; Li X; Brown JR; Qin X
    Clin Cancer Res; 2011 Nov; 17(21):6702-11. PubMed ID: 21918174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.
    Baig NA; Taylor RP; Lindorfer MA; Church AK; LaPlant BR; Pettinger AM; Shanafelt TD; Nowakowski GS; Zent CS
    J Immunol; 2014 Feb; 192(4):1620-9. PubMed ID: 24431228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.
    Golay J; Lazzari M; Facchinetti V; Bernasconi S; Borleri G; Barbui T; Rambaldi A; Introna M
    Blood; 2001 Dec; 98(12):3383-9. PubMed ID: 11719378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.
    Patz M; Isaeva P; Forcob N; Müller B; Frenzel LP; Wendtner CM; Klein C; Umana P; Hallek M; Krause G
    Br J Haematol; 2011 Feb; 152(3):295-306. PubMed ID: 21155758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
    Da Roit F; Engelberts PJ; Taylor RP; Breij EC; Gritti G; Rambaldi A; Introna M; Parren PW; Beurskens FJ; Golay J
    Haematologica; 2015 Jan; 100(1):77-86. PubMed ID: 25344523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties.
    Rafiq S; Butchar JP; Cheney C; Mo X; Trotta R; Caligiuri M; Jarjoura D; Tridandapani S; Muthusamy N; Byrd JC
    J Immunol; 2013 Mar; 190(6):2702-11. PubMed ID: 23418626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL.
    Klepfish A; Gilles L; Ioannis K; Rachmilewitz EA; Schattner A
    Ann N Y Acad Sci; 2009 Sep; 1173():865-73. PubMed ID: 19758239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia.
    Barth MJ; Czuczman MS
    Future Oncol; 2013 Dec; 9(12):1829-39. PubMed ID: 24295413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
    Reagan JL; Castillo JJ
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):151-60. PubMed ID: 21342032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity.
    Hörl S; Bánki Z; Huber G; Ejaz A; Windisch D; Muellauer B; Willenbacher E; Steurer M; Stoiber H
    Leukemia; 2013 Nov; 27(11):2200-8. PubMed ID: 23760402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ofatumumab in the treatment of chronic lymphocytic leukemia.
    Tsimberidou AM
    Drugs Today (Barc); 2010 Jul; 46(7):451-61. PubMed ID: 20683500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ofatumumab for the treatment of chronic lymphocytic leukemia.
    Grosicki S
    Expert Rev Hematol; 2015 Jun; 8(3):265-72. PubMed ID: 25882470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia.
    O'Brien S; Osterborg A
    Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):361-8. PubMed ID: 21030349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.
    Di Gaetano N; Xiao Y; Erba E; Bassan R; Rambaldi A; Golay J; Introna M
    Br J Haematol; 2001 Sep; 114(4):800-9. PubMed ID: 11564066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.